Adeno-associated virus vectors: potential applications for cancer gene therapy
Open Access
- 17 June 2005
- journal article
- review article
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 12 (12) , 913-925
- https://doi.org/10.1038/sj.cgt.7700876
Abstract
Augmenting cancer treatment by protein and gene delivery continues to gain momentum based on success in animal models. The primary hurdle of fully exploiting the arsenal of molecular targets and therapeutic transgenes continues to be efficient delivery. Vectors based on adeno-associated virus (AAV) are of particular interest as they are capable of inducing transgene expression in a broad range of tissues for a relatively long time without stimulation of a cell-mediated immune response. Perhaps the most important attribute of AAV vectors is their safety profile in phase I clinical trials ranging from CF to Parkinson's disease. The utility of AAV vectors as a gene delivery agent in cancer therapy is showing promise in preclinical studies. In this review, we will focus on the basic biology of AAV as well as recent progress in the use of this vector in cancer gene therapy.Keywords
This publication has 200 references indexed in Scilit:
- Long‐term evaluation of retinal function in Prph2Rd2/Rd2 mice following AAV‐mediated gene replacement therapyThe Journal of Gene Medicine, 2003
- Adeno-associated virus–mediated gene transfer of endostatin inhibits angiogenesis and tumor growth in vivoCancer Gene Therapy, 2002
- Functional Effect of Adeno-associated Virus Mediated Gene Transfer of Aromatic L-Amino Acid Decarboxylase into the Striatum of 6-OHDA-Lesioned RatsMolecular Therapy, 2001
- Two Animal Models of Retinal Degeneration Are Rescued by Recombinant Adeno-associated Virus-Mediated Production of FGF-5 and FGF-18Molecular Therapy, 2001
- Intracellular Trafficking of Adeno-Associated Virus Vectors: Routing to the Late Endosomal Compartment and Proteasome DegradationJournal of Virology, 2001
- γ-Rays enhance rAAV-mediated transgene expression and cytocidal effect of AAV-HSVtk/ganciclovir on cancer cellsCancer Gene Therapy, 2001
- Differential expression of a recombinant adeno-associated virus 2 vector in human CD34+ cells and breast cancer cellsCancer Gene Therapy, 2000
- Selective and Rapid Uptake of Adeno-Associated Virus Type 2 in BrainHuman Gene Therapy, 1998
- AAV as a viral vector for human gene therapyMolecular Biotechnology, 1995
- Induction of angiogenesis during the transition from hyperplasia to neoplasiaNature, 1989